Related Experiment Videos

[Chemotherapy in hormone refractory prostatic carcinoma]

B Biedermann¹, M Pless, R Herrmann

¹Abteilung für Onkologie, Kantonsspital, Basel.

Deutsche Medizinische Wochenschrift (1946)

|August 5, 1999

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14.

ESMO open·2025

Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.

ESMO open·2023

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.

ESMO open·2022

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.

ESMO open·2022

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients.

ESMO open·2021

See all related articles